ETON · ISSUER CIK 1710340
Eton Pharmaceuticals, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 Eton Pharmaceuticals, Inc. insiders reported $0.00 of open-market purchases and $10.9M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$10.9MInsider selling
−$10.9MNet open-market
Oct 6, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 6, 202616:49 | Oct 6, 2026 | ETON | Chief Business Officer | S · Sell | $55.07 | −4,166 | 43,381 | -9% | −$229K | ||
| Oct 6, 202616:49 | Oct 2, 2026 | ETON | Chief Business Officer | M · Exercise | — | +10,522 | 47,547 | +28% | — | ||
| Aug 28, 202616:51 | Aug 28, 2026 | ETON | Director | S · Sell | $59.07 | −50,000 | 59,745 | -46% | −$3.0M | ||
| Aug 28, 202616:51 | Aug 28, 2026 | ETON | Director | M · Exercise | $3.78 | +50,000 | 109,745 | +84% | $189K | ||
| Aug 24, 202617:19 | Aug 24, 2026 | ETON | Chief Business Officer | S · Sell | $65.07 | −25,000 | 37,025 | -40% | −$1.6M | ||
| Aug 24, 202617:19 | Aug 24, 2026 | ETON | Chief Business Officer | M · Exercise | $7.31 | +25,000 | 62,025 | +68% | $183K | ||
| Aug 20, 202618:26 | Aug 20, 2026from Aug 19, 2026 | ETON | President & CEO, Director | S · Sell | $60.88 | −100,000 | 961,194 | -9% | −$6.1M |